Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

In patients with diabetes, glycemic improvement by sodium-glucose cotransporter-2 inhibition depends on the kidney's ability to filter glucose. Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces hyperglycemia in patients with diabetes and normal or mildly impaired renal function...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohan, Donald E, Fioretto, Paola, Tang, Weihua, List, James F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973038/
https://www.ncbi.nlm.nih.gov/pubmed/24067431
http://dx.doi.org/10.1038/ki.2013.356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973038/
https://www.ncbi.nlm.nih.gov/pubmed/24067431
http://dx.doi.org/10.1038/ki.2013.356

Ejemplares similares